Efficacy of Lanreotide Autogel in MEN1-Related Gastrinoma: A Case Series Abstract #1012

Introduction: GEP NETs, especially gastrinomas, occur in 40-70% of MEN1 patients and represent the main cause of death in these patients.
Aim(s): To investigate the efficacy of lanreotide autogel (ATG) in the treatment of MEN1-related gastrinomas.
Materials and methods: We report a monocentric series of seven MEN1 patients (3 M, 4 F) treated with lanreotide ATG (120 mg/4 weeks) for a mean period of 62.1 months. Plasma gastrin levels have been measured at diagnosis, three months after starting lanreotide and then every six months. Five of the seven patients underwent surgery at least three months after starting lanreotide treatment, while two patients refused surgical treatment.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Laura De Marinis
Keywords: MEN1, SSA, gastrin

To read results and conclusion, please login ...

Further abstracts you may be interested in

#135 The importance of endoscopic ultrasound in detecting recurrent gastrinoma in a case of MEN 1
Introduction: Approximately 25-30% of patients have gastrinomas as part of the inherited syndrome Multiple Endocrine Neoplasia 1 (MEN 1). Gastrinomas occur in the pancreas, duodenum or peripancreatic lymph nodes. Diagnosis is made by clinical history, gastroscopy, and measurement of serum gastrin, gastric juice pH, CT scan, endoscopic ultrasound (EUS) and somatostatin receptor scintigraphy (SRS). Localization of gastrinomas in patients with MEN 1 is challenging due to their small size, frequent duodenal location, and multiplicity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis
#1207 A Novel MEN1 Gene Variant in a Sporadic Case of Multiple Endocrine Neoplasia Type 1
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the occurrence of hyperparathyroidism, pituitary adenomas and duodeno-pancreatic neuroendocrine tumours (NETs). Germline mutations of the MEN1 gene are identified in up to 87% of MEN1 families and 82% of isolated MEN1 cases.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Donato Iacovazzo
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#303 Pancreatic Metastases from Bronchopulmonary Atypical Carcinoid: An Uncommon Tumor Spreading to a Rare Location
Introduction: We report an uncommon case of pancreatic metastases from a bronchial atypical carcinoid.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#2231 Diagnostic and Clinical Management of Pancreatic Neuroendocrine in MEN1 Syndrome
Introduction: MEN1 is an autosomal dominantly inherited endocrine tumour syndrome.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: md Sabrina Chiloiro
Keywords: pancreas
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.